Prostate growth inhibition by subtype-selective alpha1-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia
BACKGROUND Recently, alpha1‐adrenoceptors (α1‐ARs) have been reported to play a prominent role in the growth of a variety of cells; however, little is known about prostate growth and subtype‐specific effects on cell proliferation. We examined the role of α1d‐AR in prostate growth and the effect of s...
Gespeichert in:
Veröffentlicht in: | The Prostate 2009-10, Vol.69 (14), p.1521-1528 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1528 |
---|---|
container_issue | 14 |
container_start_page | 1521 |
container_title | The Prostate |
container_volume | 69 |
creator | Kojima, Yoshiyuki Sasaki, Shoichi Oda, Nobuyuki Koshimizu, Taka-Aki Hayashi, Yutaro Kiniwa, Mamoru Tsujimoto, Gozoh Kohri, Kenjiro |
description | BACKGROUND
Recently, alpha1‐adrenoceptors (α1‐ARs) have been reported to play a prominent role in the growth of a variety of cells; however, little is known about prostate growth and subtype‐specific effects on cell proliferation. We examined the role of α1d‐AR in prostate growth and the effect of subtype‐selective α1‐AR antagonist, naftopidil, which has relatively higher affinity for α1d‐AR, on prostate growth in vitro and in vivo.
METHODS
First, we examined the effect of naftopidil on the cell proliferation of PrEC, PrSC, and PrSMC using WST‐1 assay. Second, we performed real‐time RT‐PCR to quantify each α1‐AR subtype mRNA expression level in a benign prostate hyperplasia (BPH) model rat, which was recently established to pathologically resemble human BPH patients. In addition, naftopidil was given to this model orally for 21 days and the proliferative and apoptotic indexes measured. Third, 18 BPH patients were administered naftopidil for 12 weeks and the proliferative and apoptotic indexes were compared before and after naftopidil administration.
RESULTS
Naftopidil significantly inhibited cell proliferation dose‐dependently in all cell lines that expressed α1d‐AR mRNA. The expression level of α1d‐AR during the growth process of the prostate in the BPH model rat was significantly higher than that in the normal prostate (P |
doi_str_mv | 10.1002/pros.21003 |
format | Article |
fullrecord | <record><control><sourceid>istex_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_21914674</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_WNG_3RH7VZJ1_Q</sourcerecordid><originalsourceid>FETCH-LOGICAL-i2463-d1abff3e5da3d7e4c8d8bfec4ad93a70d4b3d2efb1aa660a467b216d151d5f943</originalsourceid><addsrcrecordid>eNo9kM1OwzAQhC0EEqVw4Ql84Zhix0ncHlEFFFTRUv4kLtY6dlpDcCzbUPL2pC3qaUfa-Wa1g9A5JQNKSHrpfBMGaSfZAepRMuIJIVl-iHok5STJKOPH6CSED0I6D0l7qJ13RISo8dI367jCxq6MNNE0FssWh28ZW6eToGtdRvOjMdRuBTQB5bVtSu1i4zHYCMvGmhCxhSo2zihTd0lYamuWFrvdDVPiVRfmXQ3BwCk6qqAO-ux_9tHLzfXzeJJMZ7d346tpYtKsYImiIKuK6VwBU1xn5VANZaXLDNSIAScqk0ylupIUoCgIZAWXKS0UzanKq1HG-uhil-sglFBXHmxpgnDefIFvRUpHtGM2PrrzrU2t2_2eErFpVmx-ENtmxXwxe9qqjkl2TPe6_t0z4D9FwRnPxdvDrWCLCX99v6fikf0B_YeCfw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prostate growth inhibition by subtype-selective alpha1-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia</title><source>Wiley Online Library All Journals</source><creator>Kojima, Yoshiyuki ; Sasaki, Shoichi ; Oda, Nobuyuki ; Koshimizu, Taka-Aki ; Hayashi, Yutaro ; Kiniwa, Mamoru ; Tsujimoto, Gozoh ; Kohri, Kenjiro</creator><creatorcontrib>Kojima, Yoshiyuki ; Sasaki, Shoichi ; Oda, Nobuyuki ; Koshimizu, Taka-Aki ; Hayashi, Yutaro ; Kiniwa, Mamoru ; Tsujimoto, Gozoh ; Kohri, Kenjiro</creatorcontrib><description>BACKGROUND
Recently, alpha1‐adrenoceptors (α1‐ARs) have been reported to play a prominent role in the growth of a variety of cells; however, little is known about prostate growth and subtype‐specific effects on cell proliferation. We examined the role of α1d‐AR in prostate growth and the effect of subtype‐selective α1‐AR antagonist, naftopidil, which has relatively higher affinity for α1d‐AR, on prostate growth in vitro and in vivo.
METHODS
First, we examined the effect of naftopidil on the cell proliferation of PrEC, PrSC, and PrSMC using WST‐1 assay. Second, we performed real‐time RT‐PCR to quantify each α1‐AR subtype mRNA expression level in a benign prostate hyperplasia (BPH) model rat, which was recently established to pathologically resemble human BPH patients. In addition, naftopidil was given to this model orally for 21 days and the proliferative and apoptotic indexes measured. Third, 18 BPH patients were administered naftopidil for 12 weeks and the proliferative and apoptotic indexes were compared before and after naftopidil administration.
RESULTS
Naftopidil significantly inhibited cell proliferation dose‐dependently in all cell lines that expressed α1d‐AR mRNA. The expression level of α1d‐AR during the growth process of the prostate in the BPH model rat was significantly higher than that in the normal prostate (P < 0.001). Naftopidil administration inhibited cell proliferation without apoptosis in the BPH model rat and BPH patients.
CONCLUSIONS
α1d‐AR may play an important role in the regulation of cellular proliferation in the prostate, and α1d‐AR blockage by naftopidil may not only improve lower urinary tract symptoms but also inhibit prostate growth in BPH patients. Prostate 69: 1521–1528, 2009. © 2009 Wiley‐Liss, Inc.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.21003</identifier><identifier>CODEN: PRSTDS</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>alpha1-adrenoceptor subtype ; alpha1-blocker ; benign prostatic hyperplasia ; Biological and medical sciences ; cell proliferation ; Gynecology. Andrology. Obstetrics ; Male genital diseases ; Medical sciences ; Nephrology. Urinary tract diseases ; prostate growth ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>The Prostate, 2009-10, Vol.69 (14), p.1521-1528</ispartof><rights>Copyright © 2009 Wiley‐Liss, Inc.</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpros.21003$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpros.21003$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21914674$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Kojima, Yoshiyuki</creatorcontrib><creatorcontrib>Sasaki, Shoichi</creatorcontrib><creatorcontrib>Oda, Nobuyuki</creatorcontrib><creatorcontrib>Koshimizu, Taka-Aki</creatorcontrib><creatorcontrib>Hayashi, Yutaro</creatorcontrib><creatorcontrib>Kiniwa, Mamoru</creatorcontrib><creatorcontrib>Tsujimoto, Gozoh</creatorcontrib><creatorcontrib>Kohri, Kenjiro</creatorcontrib><title>Prostate growth inhibition by subtype-selective alpha1-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>BACKGROUND
Recently, alpha1‐adrenoceptors (α1‐ARs) have been reported to play a prominent role in the growth of a variety of cells; however, little is known about prostate growth and subtype‐specific effects on cell proliferation. We examined the role of α1d‐AR in prostate growth and the effect of subtype‐selective α1‐AR antagonist, naftopidil, which has relatively higher affinity for α1d‐AR, on prostate growth in vitro and in vivo.
METHODS
First, we examined the effect of naftopidil on the cell proliferation of PrEC, PrSC, and PrSMC using WST‐1 assay. Second, we performed real‐time RT‐PCR to quantify each α1‐AR subtype mRNA expression level in a benign prostate hyperplasia (BPH) model rat, which was recently established to pathologically resemble human BPH patients. In addition, naftopidil was given to this model orally for 21 days and the proliferative and apoptotic indexes measured. Third, 18 BPH patients were administered naftopidil for 12 weeks and the proliferative and apoptotic indexes were compared before and after naftopidil administration.
RESULTS
Naftopidil significantly inhibited cell proliferation dose‐dependently in all cell lines that expressed α1d‐AR mRNA. The expression level of α1d‐AR during the growth process of the prostate in the BPH model rat was significantly higher than that in the normal prostate (P < 0.001). Naftopidil administration inhibited cell proliferation without apoptosis in the BPH model rat and BPH patients.
CONCLUSIONS
α1d‐AR may play an important role in the regulation of cellular proliferation in the prostate, and α1d‐AR blockage by naftopidil may not only improve lower urinary tract symptoms but also inhibit prostate growth in BPH patients. Prostate 69: 1521–1528, 2009. © 2009 Wiley‐Liss, Inc.</description><subject>alpha1-adrenoceptor subtype</subject><subject>alpha1-blocker</subject><subject>benign prostatic hyperplasia</subject><subject>Biological and medical sciences</subject><subject>cell proliferation</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Nephrology. Urinary tract diseases</subject><subject>prostate growth</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNo9kM1OwzAQhC0EEqVw4Ql84Zhix0ncHlEFFFTRUv4kLtY6dlpDcCzbUPL2pC3qaUfa-Wa1g9A5JQNKSHrpfBMGaSfZAepRMuIJIVl-iHok5STJKOPH6CSED0I6D0l7qJ13RISo8dI367jCxq6MNNE0FssWh28ZW6eToGtdRvOjMdRuBTQB5bVtSu1i4zHYCMvGmhCxhSo2zihTd0lYamuWFrvdDVPiVRfmXQ3BwCk6qqAO-ux_9tHLzfXzeJJMZ7d346tpYtKsYImiIKuK6VwBU1xn5VANZaXLDNSIAScqk0ylupIUoCgIZAWXKS0UzanKq1HG-uhil-sglFBXHmxpgnDefIFvRUpHtGM2PrrzrU2t2_2eErFpVmx-ENtmxXwxe9qqjkl2TPe6_t0z4D9FwRnPxdvDrWCLCX99v6fikf0B_YeCfw</recordid><startdate>20091001</startdate><enddate>20091001</enddate><creator>Kojima, Yoshiyuki</creator><creator>Sasaki, Shoichi</creator><creator>Oda, Nobuyuki</creator><creator>Koshimizu, Taka-Aki</creator><creator>Hayashi, Yutaro</creator><creator>Kiniwa, Mamoru</creator><creator>Tsujimoto, Gozoh</creator><creator>Kohri, Kenjiro</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope></search><sort><creationdate>20091001</creationdate><title>Prostate growth inhibition by subtype-selective alpha1-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia</title><author>Kojima, Yoshiyuki ; Sasaki, Shoichi ; Oda, Nobuyuki ; Koshimizu, Taka-Aki ; Hayashi, Yutaro ; Kiniwa, Mamoru ; Tsujimoto, Gozoh ; Kohri, Kenjiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i2463-d1abff3e5da3d7e4c8d8bfec4ad93a70d4b3d2efb1aa660a467b216d151d5f943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>alpha1-adrenoceptor subtype</topic><topic>alpha1-blocker</topic><topic>benign prostatic hyperplasia</topic><topic>Biological and medical sciences</topic><topic>cell proliferation</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Nephrology. Urinary tract diseases</topic><topic>prostate growth</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kojima, Yoshiyuki</creatorcontrib><creatorcontrib>Sasaki, Shoichi</creatorcontrib><creatorcontrib>Oda, Nobuyuki</creatorcontrib><creatorcontrib>Koshimizu, Taka-Aki</creatorcontrib><creatorcontrib>Hayashi, Yutaro</creatorcontrib><creatorcontrib>Kiniwa, Mamoru</creatorcontrib><creatorcontrib>Tsujimoto, Gozoh</creatorcontrib><creatorcontrib>Kohri, Kenjiro</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kojima, Yoshiyuki</au><au>Sasaki, Shoichi</au><au>Oda, Nobuyuki</au><au>Koshimizu, Taka-Aki</au><au>Hayashi, Yutaro</au><au>Kiniwa, Mamoru</au><au>Tsujimoto, Gozoh</au><au>Kohri, Kenjiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prostate growth inhibition by subtype-selective alpha1-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2009-10-01</date><risdate>2009</risdate><volume>69</volume><issue>14</issue><spage>1521</spage><epage>1528</epage><pages>1521-1528</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><coden>PRSTDS</coden><abstract>BACKGROUND
Recently, alpha1‐adrenoceptors (α1‐ARs) have been reported to play a prominent role in the growth of a variety of cells; however, little is known about prostate growth and subtype‐specific effects on cell proliferation. We examined the role of α1d‐AR in prostate growth and the effect of subtype‐selective α1‐AR antagonist, naftopidil, which has relatively higher affinity for α1d‐AR, on prostate growth in vitro and in vivo.
METHODS
First, we examined the effect of naftopidil on the cell proliferation of PrEC, PrSC, and PrSMC using WST‐1 assay. Second, we performed real‐time RT‐PCR to quantify each α1‐AR subtype mRNA expression level in a benign prostate hyperplasia (BPH) model rat, which was recently established to pathologically resemble human BPH patients. In addition, naftopidil was given to this model orally for 21 days and the proliferative and apoptotic indexes measured. Third, 18 BPH patients were administered naftopidil for 12 weeks and the proliferative and apoptotic indexes were compared before and after naftopidil administration.
RESULTS
Naftopidil significantly inhibited cell proliferation dose‐dependently in all cell lines that expressed α1d‐AR mRNA. The expression level of α1d‐AR during the growth process of the prostate in the BPH model rat was significantly higher than that in the normal prostate (P < 0.001). Naftopidil administration inhibited cell proliferation without apoptosis in the BPH model rat and BPH patients.
CONCLUSIONS
α1d‐AR may play an important role in the regulation of cellular proliferation in the prostate, and α1d‐AR blockage by naftopidil may not only improve lower urinary tract symptoms but also inhibit prostate growth in BPH patients. Prostate 69: 1521–1528, 2009. © 2009 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><doi>10.1002/pros.21003</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0270-4137 |
ispartof | The Prostate, 2009-10, Vol.69 (14), p.1521-1528 |
issn | 0270-4137 1097-0045 |
language | eng |
recordid | cdi_pascalfrancis_primary_21914674 |
source | Wiley Online Library All Journals |
subjects | alpha1-adrenoceptor subtype alpha1-blocker benign prostatic hyperplasia Biological and medical sciences cell proliferation Gynecology. Andrology. Obstetrics Male genital diseases Medical sciences Nephrology. Urinary tract diseases prostate growth Tumors Tumors of the urinary system Urinary tract. Prostate gland |
title | Prostate growth inhibition by subtype-selective alpha1-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T16%3A38%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prostate%20growth%20inhibition%20by%20subtype-selective%20alpha1-adrenoceptor%20antagonist%20naftopidil%20in%20benign%20prostatic%20hyperplasia&rft.jtitle=The%20Prostate&rft.au=Kojima,%20Yoshiyuki&rft.date=2009-10-01&rft.volume=69&rft.issue=14&rft.spage=1521&rft.epage=1528&rft.pages=1521-1528&rft.issn=0270-4137&rft.eissn=1097-0045&rft.coden=PRSTDS&rft_id=info:doi/10.1002/pros.21003&rft_dat=%3Cistex_pasca%3Eark_67375_WNG_3RH7VZJ1_Q%3C/istex_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |